



SOLID TUMOR ONCOLOGY

Gain Deeper Insights With Massively Parallel Sequencing

ARUP has transitioned several solid tumor oncology tests to massively parallel sequencing (also known as next generation sequencing, or NGS) and to tumor-specific panels.

- Massively parallel sequencing provides a deeper and more accurate view of the molecular map of individual tumors.
- Tumor-specific panels are designed for the most common solid tumor types (lung cancer, colorectal cancer, and melanoma) and align with National Comprehensive Cancer Network (NCCN) guidelines for gene coverage.
- By testing multiple genes at once, panels save time and money and reduce the risk of exhausting tissue.

NEW TESTS (EFFECTIVE MAY 3, 2024)

3017203	<i>BRAF</i> Mutation Detection ¹
3017204	<i>BRAF</i> Mutation Detection with Reflex to <i>MLH1</i> Promoter Methylation ¹ (Note: The reflex test has not changed and will not be performed using NGS.)
3017209	Colorectal Cancer Mutation Panel ¹ (Note: This panel covers <i>BRAF</i> , <i>KRAS</i> , and <i>NRAS</i> .)
3017230	Lung Cancer Mutation Panel ² (Note: This panel covers <i>BRAF</i> , <i>EGFR</i> , <i>ERBB2</i> , <i>KRAS</i> , and <i>MET</i> .)
3017233	Melanoma Mutation Panel ³ (Note: This panel covers <i>BRAF</i> , <i>KIT</i> , <i>KRAS</i> , and <i>NRAS</i> .)
3017222	<i>IDH1</i> and <i>IDH2</i> Mutation Detection ⁴ (Note: This will be performed on tumor tissue only.)



TESTS INACTIVATED (EFFECTIVE MAY 20, 2024)

2002498	<i>BRAF</i> Codon 600 Mutation Detection by Pyrosequencing
0051750	<i>BRAF</i> Codon 600 Mutation Detection with Reflex to <i>MLH1</i> Promoter Methylation
0040248	<i>KRAS</i> Mutation Detection (by Pyrosequencing)
2003123	<i>NRAS</i> Mutation Detection by Pyrosequencing
2002440	<i>EGFR</i> Mutation Detection by Pyrosequencing
3004267	<i>IDH1</i> and <i>IDH2</i> Mutation Analysis Exon 4, Formalin-Fixed, Paraffin-Embedded (FFPE) Tissue

GAIN DEEPER INSIGHTS TO INFORM
TARGETED THERAPY CHOICES.
LEARN MORE:



NCCN Guidelines

1. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: colon cancer. Version 1.2022. Updated Feb 2022; accessed Oct 2022.
2. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: non-small cell lung cancer. Version 5.2022. Updated Sep 2022; accessed Oct 2022.
3. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: cutaneous melanoma. Version 2.2021. Updated Feb 2021; accessed Apr 2021.
4. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: central nervous system cancers. Version 4.2020. Updated Mar 2021; accessed Mar 2021.